Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies
Authors:
- Norma Hernández-PedroNHNorma Hernández-Pedro
- Marisol Arroyo-HernándezMAMarisol Arroyo-Hernández
- Pedro Barrios-BernalPBPedro Barrios-Bernal
- Eunice Romero-NuñezEREunice Romero-Nuñez
- Victor A. Sosa-HernandezVSVictor A. Sosa-Hernandez
- Santiago Ávila-RíosSÁSantiago Ávila-Ríos
- José Luis Maravillas-MonteroJMJosé Luis Maravillas-Montero
- Rogelio Pérez-PadillaRPRogelio Pérez-Padilla
- Diego de Miguel-PerezDiego de Miguel-Perez
- Christian RolfoCRChristian Rolfo
- Oscar ArrietaOAOscar Arrieta
Open Access
Abstract
Immune dysregulation and cancer treatment may affect SARS-CoV-2 vaccination protection. Antibody production by B-cells play a vital role in the control and clearance of the SARS-CoV-2 virus. This study prospectively explores B-cell seroconversion following SARS-CoV-2 immunization in healthy individuals and non-small cell lung cancer (NSCLC) patients undergoing oncological treatment. 92 NSCLC patients and 27 healthy individuals’ blood samples were collected after receiving any COVID-19 vaccine. Serum and mononuclear cells were isolated, and a serum surrogate virus neutralization test kit evaluated SARS-CoV-2 antibodies. B-cell subpopulations on mononuclear cells were characterized by flow cytometry. Patients were compared based on vaccination specifications and target mutation oncological treatment. A higher percentage of healthy individuals developed more SARS-CoV-2 neutralizing antibodies than NSCLC patients (63% vs. 54.3%; p = 0.03). NSCLC patients receiving chemotherapy (CTX) or tyrosine kinase inhibitors (TKIs) developed antibodies in 45.2% and 53.7%, of cases, respectively, showing an impaired antibody generation. CTX patients exhibited trends towards lower median antibody production than TKIs (1.0, IQR 83 vs. 38.23, IQR 89.22; p = 0.069). Patients receiving immunotherapy did not generate antibodies. A sub-analysis revealed that those with ALK mutations exhibited non-significant trends towards higher antibody titers (63.02, IQR 76.58 vs. 21.78, IQR 93.5; p = 0.1742) and B-cells quantification (10.80, IQR 7.52 vs. 7.22, IQR 3.32; p = 0.1382) against the SARS-CoV-2 spike protein than EGFR patients; nonetheless, these differences were not statistically significant. This study shows that antibodies against SARS-CoV-2 may be impaired in patients with NSCLC secondary to EGFR-targeted TKIs compared to ALK-directed treatment.Keywords
This publication has 18 references indexed in Scilit:
- Severity of SARS-CoV-2 infection is linked to double-negative (CD27− IgD−) B cell subset numbersInflammation Research, 2021
- Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine DosesJournal of Thoracic Oncology, 2021
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet Oncology, 2021
- Susceptibility to SARS-CoV-2 infection in patients undergoing chemotherapy and radiation therapyJournal of Infection and Public Health, 2021
- Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in JapanJAMA Oncology, 2021
- Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapyNature Cancer, 2021
- B Cell Subsets as Severity-Associated Signatures in COVID-19 PatientsFrontiers in Immunology, 2020
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyThe Lancet Oncology, 2020
- Epidermal Growth Factor Receptor Expression Licenses Type-2 Helper T Cells to Function in a T Cell Receptor-Independent FashionImmunity, 2017
- Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingBlood, 2013